StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a research report released on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock.
Aptevo Therapeutics Price Performance
APVO opened at $0.39 on Friday. The business has a 50 day simple moving average of $0.44 and a 200-day simple moving average of $2.25. Aptevo Therapeutics has a 12 month low of $0.28 and a 12 month high of $21.64.
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) EPS for the quarter, topping the consensus estimate of ($1.93) by $0.26. On average, equities research analysts predict that Aptevo Therapeutics will post -8.86 EPS for the current fiscal year.
Institutional Inflows and Outflows
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Read More
- Five stocks we like better than Aptevo Therapeutics
- How to Invest in the Best Canadian Stocks
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- Transportation Stocks Investing
- Lowe’s Stock: Hold Now, Buy it When it Dips
- What is the S&P 500 and How It is Distinct from Other Indexes
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.